MedTrace Logo

Limiting IV Chloride to Reduce AKI After Cardiac Surgery

NCT02020538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1298

Last updated 2020-04-22

No results posted yet for this study

Summary

This primary aim of this study is to test the impact of a strategy of perioperative chloride-restriction through intravenous (IV) fluid therapy on the incidence of acute kidney injury after cardiac surgery.

A prospective, open-label, single-centre 4-period sequential study of varying strategies of perioperative IV fluid composition will test the hypothesis that a perioperative protocol for the administration of chloride-poor intravenous fluids compared to chloride-rich intravenous fluids will reduce the incidence of AKI after adult cardiothoracic surgery.

Conditions

  • Patients Undergoing Cardiothoracic Surgery

Interventions

OTHER

Low-chloride perioperative intravenous fluid strategy

The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.

OTHER

High-chloride perioperative intravenous fluid strategy

Sponsors & Collaborators

  • Australian and New Zealand College of Anaesthetists

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • David R McIlroy, MBBS, MClinEpi, FANZCA · Alfred Hospital and Monash University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-03
Primary Completion
2015-12-09
Completion
2016-02-12

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02020538 on ClinicalTrials.gov